| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bc03cd73f75dc60f41b161291580d16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 |
| filingDate |
2001-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f672fed9c75b2c1810f6b2d6a423cfb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d1d7f609b44de31a147dfb9236f91fa |
| publicationDate |
2003-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1322305-A1 |
| titleOfInvention |
Use of r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature |
| abstract |
The invention relates to the use of R-enantiomers of arylpropionic acids or the pharmacologically acceptable salts or derivatives thereof, in a pure or enriched form in contrast to the racemic compound, for the production of medicaments which inhibit the activation of nuclear transcription factor AP-1 and which are suitable for treating illnesses which are influenced by said factor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012084978-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2468270-A1 |
| priorityDate |
2000-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |